Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007.

Slides:



Advertisements
Similar presentations
Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,
Advertisements

Susan Boynton, VP, Global Regulatory Affairs, Shire
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
Strengthening the Medical Device Clinical Trial Enterprise
Essential Steps to Safe, Clean Care Essential Steps AIM: Designed as a framework to support local organisations providing and commissioning health and.
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
October 3, 2006TCBC Meeting October, 2006Slide 1 TCB Code of Practice Art Wall
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
SPONSOR of 4R Nutrient Stewardship Program. The Nature Conservancy Teaming with the Florida agriculture industry to increase farmer profitability and.
Getting from Point A to Point B: What it means to bring HIVST to market Petra Stankard Technical Advisor 22 July 2014.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Chapter 13 Commercialization.
QUALITY MANAGEMENT SYSTEM ACCORDING TO ISO
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.
SECRET Green Procurement Office of Greening Government Operations May 4, 2006.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Solving the Missing Link Between Forecasting and ERP in Clinical Supply Optimization Michelle.
XIX International AIDS Conference
Introducing the Medication Recording System Schedule Ed Castagna Mom & Pop’s Small Business Services.
Saving lives with multipurpose prevention technologies for sexual and reproductive health Bethany Young Holt 1, Maggie Kilbourne-Brook 2, Jessica Cohen.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
On visible choice set and scope sensitivity: - Dealing with the impact of study design on the scope sensitivity Improving the Practice of Benefit Transfer:
Prime Responsibility for Radiation Safety
For FIGO Faculty Use Only. DO NOT COPY OR DISTRIBUTE.
Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.
Quality Reliable Safe July 2007 Medical Devices Division Features and Benefits Combiguard II® High Pressure Irrigation Splash Guard Combiport® Wound Irrigation.
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
International Partnership for Microbicides Vaginal Rings and Microbicides Mark Mitchnick, MD. October 30, 2007.
Overview of FDA's Regulatory Framework for PET Drugs
Welcome to Workshop #5: Accelerated Approval (AA) in Rare Diseases: Review of a White Paper Proposal Emil D. Kakkis, M.D., Ph.D. President and Founder.
Molecule-to-Market-Place Quality
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Microbicides The Population Council Experience and Future Directions Don E. Waldron Medical Director Don E. Waldron Medical Director.
Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.
Time and Labor Management Implementation Best Practices.
US Army Corps of Engineers BUILDING STRONG ® JACKSONVILLEMOBILESAVANNAHCHARLESTONWILMINGTON Trusted Partners Delivering Value, Today and Tomorrow IDIQs.
Forging Partnerships on Emerging Contaminants November 2, 2005 Elizabeth Southerland Director of Assessment & Remediation Division Office of Superfund.
Rectal microbicides advocacy Issues, work and collaboration Kim Mulji UK rectal microbicides working group.
Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.
Microbicide Acceptability: What We Know Elizabeth McGrory Population Council May 12, 2002.
1 Proposed Amendments to the Verification Procedure for In-Use Diesel Emission Control Strategies August 23, 2012 California Environmental Protection Agency.
Logan Gradisher Analisa Stephens. Introduction NSAID for pain and inflammation reduction – Non-steroidal anti-inflammatory drugs Localized Pain Patch.
Microbicides: New Hope for Prevention of HIV and other STIs Your name here
Responsibilities of Sponsor, Investigator and Monitor
RAC Regulatory Affairs Certification
Regulatory Considerations for Approval: FDA perspective
Guidance for review of studies involving HCT/Ps and IND Basics
Responsibilities of Sponsor, Investigator and Monitor
Rectal Microbicides: Where We’re Heading
FDA’s IDE Decisions and Communications
2 ATIS 5G OVERVIEW ATIS launched its 5G Ad Hoc in 2015 to advance regulatory imperatives, deliver an evolutionary path, address co-existence of technologies,
Deputy Director, Division of Biostatistics No Conflict of Interest
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Bozeman Health Clinical Research
Setting the Stage for PrEP Where are we now, and where should we go?
A public cervix announcement: CERVICAL BARRIERS in seven minutes
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
India Energy Congress 2013 Sustainable Sources of Energy February 2013.
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

Microbicide Applicator: Overview and Regulatory Issues WHO/ICMR/CONRAD/IPM Regulatory Issues in Microbicide Research October 30, 2007

Why Look at Delivery Systems? Microbicide gels require an applicator or delivery system for insertion into vagina. Delivery system characteristics impact correct use, dosing, acceptability and product price. Diverse populations will prefer different delivery systems. Need to plan now so a choice of delivery systems available the time of product approval.

PATH’s Work on Microbicide Delivery Systems Goal: Advance safe, cost effective delivery systems for microbicides, appropriate for women in low-resource settings. Activities: Advancing optimal vaginal applicators Evaluating SILCS diaphragm

PATH’s Vaginal Applicator Activities Consultation with US FDA Dose-delivery studies User compliance and acceptability studies Desk study Safety studies Cost analysis Scan of international manufacturers

Primary Applicators in Clinical Trials Most trials using prefilled, single- use, plastic applicators Optimal for clinical trials Ensures correct dose in applicator Blinds to product use Reduces variability between trials Reduces user variability

Gel Applicators: Prefilled, Single Use Pros: Commonly used in clinical trials High degree of user acceptance in acceptability literature* Cons: Cost likely higher than user-filled or reusable devices Product use linked to timing of sex--challenge for discreet use Portability, storage, disposal could be a challenge Lack of appropriate designs for rectal use *Cohen 2007, Kilmarx 2006, Whitehead 2006, Morrow 2003, Coetzee 2001, Hardy 1998, LePage Coitally Dependent

Gel Applicators: User Filled, Reusable or Single Use Pros: May provide benefits related to cost Alternative materials (e.g., paper) allow for clean, efficient disposal Reusable design can minimize storage/portability requirements Cons: Potential user concern with hygiene of reusable applicators* Difficult to ensure proper filling/dose delivery Requires additional step for user *Cohen 2007, Bentley 2004, Morrow Coitally Dependent

Clinical Study Confirms Applicator Safety* Objectives Assess effect of applicator on signs and symptoms of irritation of external genitalia, cervix, and vagina as seen on colposcopy after a single use Results No severe cervical or vaginal lesions. HTI single-use, HTI user-filled, and Norden-Pac single-use applicators appear safe from perspective of causing severe or repeated vaginal trauma HTI single-use HTI user-filled Norden-Pac single-use *Brache, 2006

Acceptability Study ( ) Objective Characterize women’s PREFERENCES regarding applicator features (cost, reuse versus single use, safety). Results Single use applicator preferred Preference related to perceived quality and safety

Sample Applicator Cost Estimates (2004) ApplicatorApplicator filling Microbicide tube + tube filling Total cost per use HTI prefilled10¢25¢–40¢35¢–50¢ Norden-Pac prefilled 4¢6¢–15¢10¢–19¢ Tekpack user-filled (PAPER) 3¢17¢ + 35¢8.2¢* HTI user- filled (plastic) 8¢17¢ + 35¢6¢** * Assuming microbicide tube contains 10 doses and 10 applicators are used. **Assuming microbicide tube contains 10 doses and applicator is reused 10 times.

One Option for Alternative Microbicide Delivery User Filled Could lower cost by as much as $0.42 per dose Single Use Addresses concerns about spreading germs Paper Burns easily for disposal Example of a user-filled, paper applicator (TEKPAK, Inc.)

Case Study: FDA Consultation for a User-Filled, Paper Applicator Microbicide delivered with a user-filled applicator vs. a prefilled applicator. What data is required to establish equivalence if a sponsor wants to incorporate user-filled applicator in an application for market approval? User-filled, paper applicator

Possible Scenario for Bridging Studies Phase 3 Clinical Trial Microbicide A + Applicator A Bridging Studies Microbicide A + Applicator B

Possible Scenario for Bridging Studies Regulatory Submission Microbicide A + Applicator A, B Phase 3 Clinical Trial Microbicide A + Applicator A Bridging Studies Microbicide A + Applicator B

Possible Scenario for Bridging Studies Regulatory Submission Microbicide A + Applicator A, B Product Introduction In India Microbicide A + Applicator A, B

Next Steps for Microbicide Delivery Developing standard rectal microbicide applicator Improving dosing with user-filled applicators Evaluating diaphragms for microbicide delivery

SILCS Diaphragm: a new single-size cervical barrier Single size fits most women Easy to supply and provide Easy to insert and remove Comfortable for both partners Easy to wash and reuse

SILCS Diaphragm Microbicide Delivery System Combines chemical and physical barrier protection Offers dual protection Holds microbicide high in vagina Extends time from gel application to sex May reduce stigma Reduces need for an applicator

SILCS Microbicide Delivery System—current research Feasibility/acceptability of applying gel to both sides of diaphragm for added protection Impact of gel volume on women’s experience of handling and acceptability of SILCS Gel volume required on cervical and vaginal sides for comparable coverage/protection Comparative acceptability of different gel application methods when used by couples

SILCS Diaphragm and controlled release delivery Preliminary feasibility assessment of SILCS diaphragm as a controlled-release delivery device Laboratory testing for material compatibility Queens University of Belfast

Questions for Regulatory Consideration What is the regulatory pathway for seeking approval of an alternative delivery system? What bridging data will be required to confirm equivalence for safety and efficacy with prefilled applicators? How will data required change depending on the delivery system proposed?

Questions for Regulatory Consideration How can this guidance be shared with researchers/study sponsors? What next steps are needed to support this discussion among Asian regulatory authorities?

Optimizing Microbicide Delivery The more options, the better!

Thank you to our Donors ! USAID CONRAD amfAR PATH

Jessica Cohen Program Officer Maggie Kilbourne-Brook Program Officer